MGMaatje D. A. van Gastel

Maatje D. A. van Gastel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maatje D. A. van Gastel has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Ron Gansevoort

    Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    10 shared publications
  • Ron T. Gansevoort

    Department Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    7 shared publications
  • Esther Meijer

    Department of Nephrology, University Medical Center Groningen, Groningen, the Netherlands

    5 shared publications
  • Niek F. Casteleijn

    Department of Urology, University Medical Center Groningen, Groningen, the Netherlands

    5 shared publications
  • A. Lianne Messchendorp

    Department of Nephrology, University Medical Center Groningen, Groningen, the Netherlands

    4 shared publications
  • Darius Soonawala

    Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; Department of Internal Medicine, Haga teaching hospital, The Hague, The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Effects of the GnRH agonist leuprorelin on liver volume in premenopausal women with severe polycystic liver disease

    by Inge G. Wijbenga, Renee Duijzer, Paul Geertsema, Sophie E. Aapkes, Thomas Bais, Lianne A. Messchendorp, Priya Vart, Robbert J. de Haas, Marjan van Den Berg, Hans Blokzijl, et al.

    Background: Polycystic liver disease (PLD) is characterized by multiple liver cysts, sometimes leading to severe liver enlargement, with associated physical and psychosocial complaints. Treatment options are limited. Female gender is a risk factor for PLD; estrogen supplementation increases liver size in women with PLD, whereas the polycystic liver decreases after menopause. Estrogens may therefore be a target for therapy. Methods: In this prospective, open-label study, premenopausal women aged 18−45 years with severe PLD were randomized 1:1 to a direct start of the gonadotropin-releasing hormone agonist leuprorelin (n=6) or to standard care with delayed start of leuprorelin 18 months after randomization (n=8). The gonadotropin-releasing hormone agonist (11.25 mg injections once every 3 mo) leads to a reduction in estrogens and progesterone, and consequently to medically induced menopause. The primary outcome was liver growth rate at 18 months. Secondary outcomes comprised quality of life, menopausal side effects, and adverse events. An interim analysis was performed when all participants had reached month 18, as notable side effects were expressed. Results: In the group with direct start of leuprorelin, liver volume still increased in half of the participants, with the median liver growth rate not significantly different from the standard care group (4.04 [−4.62 to 6.84] vs. 11.0 [0.70−13.2] %/year, respectively, p =0.15). Importantly, PLD-related quality of life did not improve with treatment, whereas menopausal side effects were severe, leading one participant to stop treatment early. The total number of adverse events in the direct versus standard care group was 38 versus 9, respectively ( p Conclusions: leuprorelin treatment did not reverse liver volume, while menopausal side effects and adverse events were substantial.

  • Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study

    by Ruben Bouma, Olaf P. Geerse, Natasja J. H. Raijmakers, Heidi P. Fransen, Lia van Zuylen, Anna K. L. Reyners, Kristel van Asselt, Maatje D. A. van Gastel, Daan Brandenbarg, Mariken E. Stegmann

    Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.

  • Open Access

    Sex-Specific Determinants of the Ketone Body β-Hydroxybutyrate in the General Population

    by Martine G E Knol, Amarens van der Vaart, Lyanne Kieneker, Margery A Connelly, Stephan J L Bakker, Roman-Ulrich Müller, Markus M Rinschen, Ron T Gansevoort, Maatje D A van Gastel

    Context: Being in a state of ketosis has been associated with numerous positive health outcomes and is currently studied in various medical fields. However, the influence of factors other than diet on ketone body levels in the general population has not yet been investigated. Objective: This study aimed to investigate factors that are associated with plasma levels of the ketone body β-hydroxybutyrate (BHB) levels in a general population cohort. Methods: We included 6102 participants with available plasma BHB data from the Prevention of Renal and Vascular End-stage Disease (PREVEND) population-based cohort study. Fasting plasma BHB was measured using nuclear magnetic resonance spectroscopy. Determinants of BHB concentrations were identified using univariable and stepwise backward regression analyses. Results: Women had significantly higher BHB levels than men (123 [interquartile range (IQR) 94-175] vs 119 [IQR 92-164] µmol/L, respectively; P < .001). In women, hormonal status was the most significant determinant of BHB levels. In a multivariable-adjusted model, oral contraceptive (OC) use was associated with a 45% increase in BHB concentration, whereas postmenopausal status was associated with an 11% decrease compared to premenopausal women without OC use. In men, age was the most significant determinant, with a 1% increase in BHB levels per year. In both sexes, other determinants of higher BHB levels were lower protein intake, habitual alcohol use, higher N-terminal pro-B-type natriuretic peptide, and a higher free thyroxine level. Conclusion: A complex interplay of metabolic, hormonal, and lifestyle factors are associated with BHB levels in the general population, with distinct sex differences. In women, hormonal status was the most important factor, while in men increasing age was the most significant factor affecting BHB levels.


  • Open Access

    Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD

    by Thomas Bais, Paul Geertsema, Martine G.E. Knol, Maatje D.A. van Gastel, Robbert J. de Haas, Esther Meijer, Ron T. Gansevoort

    Background: The Mayo Imaging Classification was developed to predict the rate of disease progression in patients with autosomal dominant polycystic kidney disease. This study aimed to validate its ability to predict kidney outcomes in a large multicenter autosomal dominant polycystic kidney disease cohort. Methods: Included were patients with ≥1 height-adjusted total kidney volume (HtTKV) measurement and ≥3 eGFR values during ≥1-year follow-up. Mayo HtTKV class stability, kidney growth rates, and eGFR decline rates were calculated. The observed eGFR decline was compared with predictions from the Mayo Clinic future eGFR equation. The future eGFR prediction equation was also tested for nonlinear eGFR decline. Kaplan–Meier survival analysis and Cox regression models were used to assess time to kidney failure using Mayo HtTKV class as a predictor variable. Results: We analyzed 618 patients with a mean age of 47±11 years and mean eGFR of 64±25 ml/min per 1.73 m 2 at baseline. Most patients (82%) remained in their baseline Mayo HtTKV class. During a mean follow-up of 5.1±2.2 years, the mean total kidney volume growth rates and eGFR decline were 5.33%±3.90%/yr and −3.31±2.53 ml/min per 1.73 m 2 per year, respectively. Kidney growth and eGFR decline showed considerable overlap between the classes. The observed annual eGFR decline was not significantly different from the predicted values for classes 1A, 1B, 1C, and 1D but significantly slower for class 1E. This was also observed in patients aged younger than 40 years and older than 60 years and those with PKD2 mutations. A polynomial model allowing nonlinear eGFR decline provided more accurate slope predictions. Ninety-seven patients (16%) developed kidney failure during follow-up. The classification predicted the development of kidney failure, although the sensitivity and positive predictive values were limited. Conclusions: The Mayo Imaging Classification demonstrated acceptable stability and generally predicted kidney failure and eGFR decline rate. However, there was marked interindividual variability in the rate of disease progression within each class.


  • Open Access

    Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD

    by Martine G E Knol, Thomas Bais, Paul Geertsema, Margery A Connelly, Stephan J L Bakker, Ron T Gansevoort, Maatje D A van Gastel, the DIPAK Consortium, J P H Drenth, J W de Fijter, et al.

    Dysregulated energy metabolism is a recently discovered key feature of autosomal dominant polycystic kidney disease (ADPKD). Cystic cells depend on glucose and are poorly able to use other energy sources such as ketone bodies. Raising ketone body concentration reduced disease progression in animal models of polycystic kidney diseases. Therefore, we hypothesized that higher endogenous plasma beta-hydroxybutyrate (BHB) concentrations are associated with reduced disease progression in patients with ADPKD. We analyzed data from 670 patients with ADPKD participating in the Developing Intervention Strategies to Halt Progression of ADPKD (DIPAK) cohort, a multi-center prospective observational cohort study. BHB was measured at baseline using nuclear magnetic resonance spectroscopy. Participants were excluded if they had type 2 diabetes, were using disease-modifying drugs (e.g. tolvaptan, somatostatin analogs), were not fasting or had missing BHB levels, leaving 521 participants for the analyses. Linear regression analyses were used to study cross-sectional associations and linear mixed-effect modeling for longitudinal associations. Of the participants, 61% were female, with an age of 47.3 ± 11.8 years, a height-adjusted total kidney volume (htTKV) of 834 [interquartile range (IQR) 495–1327] mL/m and an estimated glomerular filtration rate (eGFR) of 63.3 ± 28.9 mL/min/1.73 m2. The median concentration of BHB was 94 (IQR 68–147) µmol/L. Cross-sectionally, BHB was associated neither with eGFR nor with htTKV. Longitudinally, BHB was positively associated with eGFR slope {B = 0.35 mL/min/1.73 m2 [95% confidence interval (CI) 0.09 to 0.61], P = .007}, but not with kidney growth. After adjustment for potential confounders, every doubling in BHB concentration was associated with an improvement in the annual rate of eGFR by 0.33 mL/min/1.73 m2 (95% CI 0.09 to 0.57, P = .008). These observational analyses support the hypothesis that interventions that raise BHB concentration could reduce the rate of kidney function decline in patients with ADPKD.


  • Open Access

    Validation of a semi-automatic method to measure total liver volumes in polycystic liver disease on computed tomography — high speed and accuracy

    by Sophie E. Aapkes, Thijs R. M. Barten, Walter Coudyzer, Joost P. H. Drenth, Ivo M. A. Geijselaers, Sterre A. M. ter Grote, Ron T. Gansevoort, Frederik Nevens, Maatje D. A. van Gastel

    Objectives: Polycystic liver disease (PLD) is characterized by growth of hepatic cysts, causing hepatomegaly. Disease severity is determined using total liver volume (TLV), which can be measured from computed tomography (CT). The gold standard is manual segmentation which is time-consuming and requires expert knowledge of the anatomy. This study aims to validate the commercially available semi-automatic MMWP (Multimodality Workplace) Volume tool for CT scans of PLD patients. Methods: We included adult patients with one (n = 60) or two (n = 46) abdominal CT scans. Semi-automatic contouring was compared with manual segmentation, using comparison of observed volumes (cross-sectional) and growth (longitudinal), correlation coefficients (CC), and Bland-Altman analyses with bias and precision, defined as the mean difference and SD from this difference. Inter- and intra-reader variability were assessed using coefficients of variation (CV) and we assessed the time to perform both procedures. Results: Median TLV was 5292.2 mL (IQR 3141.4–7862.2 mL) at baseline. Cross-sectional analysis showed high correlation and low bias and precision between both methods (CC 0.998, bias 1.62%, precision 2.75%). Absolute volumes were slightly higher for semi-automatic segmentation (manual 5292.2 (3141.4–7862.2) versus semi-automatic 5432.8 (3071.9–7960.2) mL, difference 2.7%, p < 0.001). Longitudinal analysis demonstrated that semi-automatic segmentation accurately measures liver growth (CC 0.908, bias 0.23%, precision 4.04%). Inter- and intra-reader variability were small (2.19% and 0.66%) and comparable to manual segmentation (1.21% and 0.63%) (p = 0.26 and p = 0.37). Semi-automatic segmentation was faster than manual tracing (19 min versus 50 min, p = 0.009). Conclusions: Semi-automatic liver segmentation is a fast and accurate method to determine TLV and liver growth in PLD patients. Key Points: • Semi-automatic liver segmentation using the commercially available MMWP volume tool accurately determines total liver volume as well as liver growth over time in polycystic liver disease patients. • This method is considerably faster than manual segmentation through the use of Hounsfield unit settings. • We used a real-life CT set for the validation and showed that the semi-automatic tool measures accurately regardless of contrast used for the CT scan or not, presence of polycystic kidneys, liver volume, and previous invasive treatment for polycystic liver disease.


  • Automated Kidney and Liver Segmentation in MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease: A Multicenter Study

    by Piotr Woznicki, Florian Siedek, Maatje D.A. van Gastel, Daniel Pinto dos Santos, Sita Arjune, Larina A. Karner, Franziska Meyer, Liliana Lourenco Caldeira, Thorsten Persigehl, Ronald T. Gansevoort, et al.

    Key Points: We developed a model for automated kidney and liver volumetry in ADPKD to provide assistance with time-consuming volumetry. The model works in both coronal and axial planes and was tested in the real-life setting using large multicentric cohorts. The trained model is published along with the code to allow for further joint development and integration into commercial software packages. Background: Imaging-based total kidney volume (TKV) and total liver volume (TLV) are major prognostic factors in autosomal dominant polycystic kidney disease (ADPKD) and end points for clinical trials. However, volumetry is time consuming and reader dependent in clinical practice. Our aim was to develop a fully automated method for joint kidney and liver segmentation in magnetic resonance imaging (MRI) and to evaluate its performance in a multisequence, multicenter setting. Methods: The convolutional neural network was trained on a large multicenter dataset consisting of 992 MRI scans of 327 patients. Manual segmentation delivered ground-truth labels. The model’s performance was evaluated in a separate test dataset of 93 patients (350 MRI scans) as well as a heterogeneous external dataset of 831 MRI scans from 323 patients. Results: The segmentation model yielded excellent performance, achieving a median per study Dice coefficient of 0.92–0.97 for the kidneys and 0.96 for the liver. Automatically computed TKV correlated highly with manual measurements (intraclass correlation coefficient [ICC]: 0.996–0.999) with low bias and high precision (−0.2%±4% for axial images and 0.5%±4% for coronal images). TLV estimation showed an ICC of 0.999 and bias/precision of −0.5%±3%. For the external dataset, the automated TKV demonstrated bias and precision of −1%±7%. Conclusions: Our deep learning model enabled accurate segmentation of kidneys and liver and objective assessment of TKV and TLV. Importantly, this approach was validated with axial and coronal MRI scans from 40 different scanners, making implementation in clinical routine care feasible. Clinical Trial registry name and registration number: The German ADPKD Tolvaptan Treatment Registry (AD[H]PKD), NCT02497521


  • Open Access

    The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: an observational cohort study

    by Martine G E Knol, Bart J Kramers, Ron T Gansevoort, Maatje D A van Gastel

    Mammalian target of rapamycin (mTOR) inhibitors and ketogenesis have been shown to ameliorate disease progression in experimental autosomal dominant polycystic kidney disease (ADPKD). Glucagon is known to lower mTOR activity and stimulate ketogenesis. We hypothesized that in ADPKD patients, higher endogenous glucagon is associated with less disease severity and progression. Data were analysed from 664 Dutch ADPKD patients participating in the Developing Intervention Strategies to Halt Progression of ADPKD observational cohort, including patients >18 years of age with an estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2 and excluding patients with concomitant diseases or medication use that may impact the natural course of ADPKD. The association between glucagon and disease severity and progression was tested using multivariate linear regression and mixed modelling, respectively. The median glucagon concentration was 5.0 pmol/L [interquartile range (IQR) 3.4–7.2) and differed significantly between females and males [4.3 pmol/L (IQR 2.9–6.0) and 6.6 (4.5–9.5), P < 0.001, respectively]. Intrasubject stability of glucagon in 30 patients showed a strong correlation (Pearson’s correlation coefficient 0.893; P < 0.001). Moreover, glucagon showed significant associations with known determinants (sex, body mass index and copeptin; all P < 0.01) and known downstream effects (glucose, haemoglobin A1c and cholesterol; all P < 0.05), suggesting that glucagon was measured reliably. Cross-sectionally, glucagon was associated with eGFR and height-adjusted total kidney volume, but in the opposite direction of our hypothesis, and these lost significance after adjustment for confounders. Glucagon was not associated with an annual decline in kidney function or growth in kidney volume. These data do not provide evidence for a role of endogenous glucagon as a protective hormone in ADPKD. Intervention studies are needed to determine the relation between glucagon and ADPKD.


  • Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

    by Rene M.M. van Aerts, Wietske Kievit, Hedwig M.A. D’aGnolo, Charles J. Blijdorp, Niek F. Casteleijn, Shosha E.I. Dekker, Johan W. de Fijter, Maatje van Gastel, Tom J. Gevers, Liyanne F.M. van de Laarschot, et al.


  • Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease

    by Maatje D.A. van Gastel, Marie E. Edwards, Vicente E. Torres, Bradley J. Erickson, Ron T. Gansevoort, Timothy L. Kline

    Significance Statement: Because renal function often remains stable in the early stages of autosomal dominant polycystic kidney disease (ADPKD), total kidney volume (TKV) is the most important biomarker of disease severity and progression. The authors developed and validated a fully automated method of simultaneously measuring TKV and total liver volume (TLV) as well as their growth rates from magnetic resonance images. Their findings indicate that the method’s performance is equivalent to the gold standard of manual tracing while requiring a fraction of the time and skill. This approach may address the unmet need for rapid and reliable assessment of TKV and TLV, allowing identification of patients with rapidly progressing ADPKD for emerging drug treatments and serving as a reliable alternative for assessment of disease progression in clinical trials. Background: The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. Methods: We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method’s performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. Results: TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and −1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and −1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. Conclusions: These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.